Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls

Lund, Sweden, June 7, 2019 - Hansa Biopharma AB (”Hansa”) (NASDAQ Stockholm: HNSA ), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIXTM (imlifidase), the company’s novel IgG-degrading enzyme, was highlighted in three presentations at the 2019 American Transplant Congress (ATC), which was held from June 1 – 5, 2019 in Boston, Massachusetts, USA. In a plenary presentation on June 5, 2019, Dr. Edmund Huang, MD, Associate Professor and Transplant Nephrologist at the Kidney and Pancreas Transplant Center at Cedars-Sinai Medical Center in Los Angeles, presented “ Three-year Outcomes of Highly-sensitized Kidney Transplant Recipients Desensitized w ith Ig G Endopeptidase .” The plenary abstract, by Dr. Huang and Stanley Jordan M.D., Director Kidney Transplantation and Transplant Immunology at the Cedars-Sinai Medical Center in Los Angeles, won the ATC’s People’s Choice Award, as voted by the ATC attendees to be the most impactful to the transplant community. In his presentation, Dr. Huang reported a statistically significant reduction in time on the waitlist for transplantation among imlifidase treated patients compared to similarly sensitized matched controls. The matched control analysis showed statistically significant shorter time to transplant in both the current and previous U.S. Kidney Allocation System (KAS). "Our matched control analysis showed statistically significant shorter time to transplant in the pre and post- KAS era. We are therefore convinced that Imlifidase complements the new KAS system and will facilitate reduced time to kidney transplantation in highly sensitized patients.” commented Dr. Huang “We have previously demonstrated that treatment with imlifidase enables life-saving kidney transplantation that would otherwise not be possible. This matched control analysis further illustrates shorter time to transplant for these highly sensitized patients” commented Dr. Jordan. The presentation also reported follow up data from the U.S. investigator-initiated Phase 2 study of imlifidase for kidney transplantation in highly sensitized patients. Results show excellent graft survival out to three years with graft survival in line with deceased donor transplantation of non-sensitized patients. One death, unrelated to imlifidase treatment and the kidney transplant, occurred 10 months after transplant. There were sporadic cases of late rebound DSA, but most remained DSA-free up to 36 months post-transplant. In an oral presentation on June 2, 2019, Robert A. Montgomery, M.D., Director, NYU Langone Transplant Institute, New York City, presented “ Safety a nd Efficacy o f Imlifidase i n Highly- S ensitized Kidney Transplant Patients: Results f rom a Phase 2 Study .” “The safety and efficacy data on imlifidase provide hope to highly sensitized patients, who today are very difficult or impossible to transplant, and face an extremely poor prognosis. Six months follow up results continue to show that imlifidase has enabled all patients to undergo transplantation resulting in good kidney function and graft survival,” Robert A. Montgomery, M.D., Director, NYU Langone Transplant Institute, New York City. In a poster session on June 2, 2019, Dr. Matthew J. Everly, Director of the Terasaki Research Institute in Los Angeles, presented “ A Prognostic Drug Development Tool t o Assess t he Transplantability a t t he Time o f Listing f or Kidney Transplant Candidates .” In his poster session Dr. Everly reported on the results of simulations done in highly sensitized patients, which demonstrated that transplant rates could be increased by 25% if there were a therapy to address the HLA antibody barrier. References https://optn.transplant.hrsa.gov The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on June 7, 2019. For further information, please contact: Company: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 733-328 634 E-mail: [email protected] Swedish Investor and Media Relations: Cord Communications Mikael Widell +46 70-311 99 60 U.S. Investor and Media Relations: Argot Partners Stephanie Marks / David Rosen (media) +1 212 600 1902

The release as fetched from its publisher. hansabiopharma.com ↗